How KISQALI Works
Find out how this combination treatment works.
Live Longer with KISQALI
Overall Survival Results
Living Longer is Possible and Proven With KISQALI
KISQALI® (ribociclib) is approved for both pre- and postmenopausal women with HR+, HER2- metastatic breast cancer (mBC). KISQALI has extended lives in multiple clinical trials when taken in combination with a nonsteroidal aromatase inhibitor or fulvestrant. Watch the video below to find out what it means to be a Thriver with mBC and why women are asking for KISQALI by name.
See Premenopausal Results > | See Postmenopausal Results >
Results for Premenopausal Women Taking KISQALI + a Nonsteroidal Aromatase Inhibitor + Goserelin
KISQALI was studied in a clinical trial dedicated exclusively to younger women. The median age was 44 years (range 25 to 58). 495 women were treated with KISQALI + a nonsteroidal aromatase inhibitor (NSAI) (ie letrozole or anastrozole) + goserelin or an NSAI + goserelin.
Overall survival
In a clinical trial, KISQALI + an NSAI + goserelin extended the length of time women were alive from the start of treatment—also called overall survival (OS). Median OS is the length of time when half of the women were still alive. At a 54-month observational check in, results showed the median overall survival (OS) was 58.7 months for KISQALI + an NSAI + goserelin vs 47.7 months for placebo + an NSAI + goserelin. This 54-month analysis was not pre-planned to detect a false positive or show a difference between treatments. KISQALI is not approved for use with tamoxifen.
Median progression-free survival
In the same clinical trial at 35-month check in, half the women taking KISQALI + an NSAI + goserelin still showed no disease progression after 27.5 months vs 13.8 months for women taking placebo + an NSAI + goserelin. Median progression-free survival (PFS) is the length of time when half of the women had not yet progressed.
Proven to shrink tumors
KISQALI + an NSAI + goserelin worked together to shrink tumors in women who had measurable tumors. This check in was not designed to measure tumor size reduction. Based on the design of the trial, this result may not have been caused by the treatment.
Results for Postmenopausal Women Taking KISQALI + Fulvestrant
In a clinical trial with 726 women, 484 were treated with KISQALI + fulvestrant and 242 women were treated with fulvestrant alone.
Overall survival
In a clinical trial, KISQALI + fulvestrant extended the length of time women were alive from the start of treatment—also called overall survival (OS). Median OS is the length of time when half of the women were still alive. At a 56-month observational check in, results showed the median overall survival (OS) was 53.7 months for KISQALI + fulvestrant vs 41.5 months for placebo + fulvestrant. This 56-month analysis was not pre-planned to detect a false positive or show a difference between treatments.
Median progression-free survival
In the same clinical trial at 39-month check in, half the women taking KISQALI + fulvestrant still showed no disease progression after 20.5 months vs 12.8 months for women taking placebo + fulvestrant. Median progression-free survival (PFS) is the length of time when half of the women had not yet progressed.
Proven to shrink tumors
KISQALI + fulvestrant worked together to shrink tumors in women who had measurable tumors. This check in was not designed to measure tumor size reduction. Based on the design of the trial, this result may not have been caused by the treatment.
